Published in final edited form as:

Horm Cancer. 2013 December ; 4(6): . doi:10.1007/s12672-013-0157-7.

Ligand-Activated Peroxisome Proliferator-activated Receptor β/δ Modulates Human Endometrial Cancer Cell Survival

JJ MA^{1,2,*}, D Monsivais^{1,*}, MT Dyson¹, JS Coon V¹, S Malpani¹, M Ono¹, H Zhao¹, H Xin¹, ME Pavone¹, JJ Kim¹, D Chakravarti¹, and SE Bulun¹

¹Division of Reproductive Biology Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611

²Department of Obstetrics and Gynecology, Xijing Hospital Fourth Military Medical University, Xi'an China 710032

Abstract

Endometrial cancer is the fourth most common malignancy among women and is a major cause of morbidity- contributing to approximately 8,200 annual deaths in the United States. Despite advances to the understanding of endometrial cancer, novel interventions for the disease are necessary given that many tumors become refractory to therapy. As a strategy to identify novel therapies for endometrial carcinoma, in this study we examined the contribution of the peroxisome proliferator-activated receptor / (PPAR /) to endometrial cancer cell proliferation and apoptosis. We found that when activated with the highly selective PPAR / agonists, GW0742 and GW501516, PPAR / inhibited the proliferation and markedly induced the apoptosis of three endometrial cancer cell lines. The specificity of the PPAR / -induced effects on cell proliferation and apoptosis was demonstrated using PPAR / -selective antagonists and PPAR / siRNA in combination with PPAR / -selective agonists. Furthermore, we showed that PPAR / activation increased PTEN expression, which led to AKT and GSK3 dephosphorylation, and increased -catenin phosphorylation associated with its degradation. Overall, our data suggest that the anti-tumorigenic effect of PPAR / activation in endometrial cancer is mediated through the negative regulation of the AKT/GSK3 / -catenin pathway. These findings warrant further investigation of PPAR / as a therapeutic target in endometrial cancer.

Keywords

endometrial cancer; peroxisome proliferator-activated receptor / ; glycogen synthase kinase 3; AKT; proliferation; apoptosis

Introduction

Estimates predict that 49,500 women are affected with endometrial cancer every year and that 8,200 die as a result of the disease in the United States [1,2]. Despite progress in endometrial cancer treatments, current treatments often fail to control tumor recurrence and metastasis. For example, although 75% of all endometrial cancers are treated at an early

Corresponding author: Serdar E. Bulun, M.D., Division of Reproductive Biology Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, 250 E. Superior Street, Suite 3-2306, Chicago, Illinois 60611-2914, Tel: 312-472-3980, Fax: 312-472-3740, s-bulun@northwestern.edu.

*J.J.M. and D.M. contributed equally to this work.

Conflict of interest

The authors declare no conflicts of interest.

stage, it is estimated that 15% to 20% of all cases recur [3]. As no new targeted therapies are available in standard clinical care and response to conventional systemic therapy is limited, identification of novel therapeutic targets is urgently needed to improve endometrial cancer treatment efficacy [4].

An increasing body of evidence suggests that peroxisome proliferator-activated receptors (PPARs) contribute to the development of some solid tumors [5]. PPARs are members of the steroid hormone receptor superfamily; the three distinct isoforms— α , β , and γ —act as ligand-activated transcription factors [6]. In the last 20 years, PPARs have gone from being virtually unknown to being recognized as major players in numerous physiological functions and pathological conditions, including the development of chronic diseases such as diabetes, obesity, atherosclerosis, and cancer [7,8]. PPAR γ is found predominantly in the nucleus and can be co-immunoprecipitated with its heterodimerization partner, retinoid X receptor (RXR) [9]. Although there are limited reports describing the biological function of PPAR γ in endometrial cancer, in situ hybridization and immunohistochemistry demonstrate that PPAR γ levels are higher in endometrial cancer specimens compared with controls [10].

PPAR α and β subtypes are known to have fundamental roles in cell proliferation/apoptosis and carcinogenesis [11]. However, conflicting data regarding the role of PPAR γ in the development of cancer, suggest that the exact contribution of PPAR γ to cancer cell proliferation or apoptosis has yet to be established. In particular, observations from previous studies raise the possibility of cell type- and organ-specific effects mediated by PPAR γ [12]. It is well known that RAR α and PPAR γ complement each other and contribute to the regulation of cell proliferation and apoptosis [13]. Schug et al., demonstrated this mechanism by elucidating that the proliferative effect of PPAR γ was mediated through a high FABP5:CRABP2 ratio, which diverted *all-trans* retinoic acid (atRA) away from RAR α toward PPAR γ , which then led to anti-apoptotic events and increased proliferation [13]. However, studies in other cell types have found conflicting suggesting that the activity of PPAR γ is tissue-specific [14].

Our lab previously demonstrated that the selective RAR α agonist, AM580, directly regulates endometrial Ishikawa cell proliferation and apoptosis; thus, RA signaling via RAR α /RXR activation may play a critical role in mediating the carcinogenesis of human endometrial cancer [15]. However, the role of PPAR γ in endometrial carcinoma has not been established. Given the therapeutic potential of PPAR γ agonists, which have been examined in clinical trials [16], we wanted to understand the function and the underlying mechanisms of PPAR γ activation in endometrial cancer. We hypothesized that PPAR γ and its downstream pathways are effective targets that inhibit endometrial cancer cell proliferation and survival. To test our hypothesis, we evaluated the effects of ligand activation, antagonism, and silencing of PPAR γ on cell proliferation and apoptotic pathways in the Ishikawa, Sawano, and RL-95 human endometrial cancer cell lines.

Materials and methods

Materials

Two highly selective PPAR γ -selective agonists, GW0742 and GW501516 [17], and an RAR α -selective agonist, TTNPB, were purchased from Tocris Bioscience (Minneapolis, MN, USA). GW0742 and GW501516 were dissolved in dimethyl sulfoxide (DMSO). Two highly selective PPAR γ selective RA antagonists, GSK3787 and GSK0660, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Cell cultures

Endometrial cancer cell lines Ishikawa (grade 1 with PTEN and p53 mutations), RL95-2 (grade 2 GW501516 with PTEN and p53 mutations), and Sawano (naturally raised cisplatin-resistant cells) were purchased from ATCC (Manassas, VA, USA). Ishikawa cells were maintained in DMEM-F12 medium (GIBCO®, Life Technologies, NY, USA) supplemented with 5% fetal bovine serum (FBS) and 500 units/ml penicillin/streptomycin. RL95-2 cells were maintained in DMEM-F12 medium (GIBCO, Life Technologies) supplemented with 10% FBS, 500 units/ml penicillin/streptomycin, and 1 mM insulin. Sawano cells were maintained in MEM medium (GIBCO, Life Technologies) supplemented with 10% FBS, 500 units/ml penicillin/streptomycin, and 1 mM glutamax. Human Keratinocytes (HaCaT cells) were cultured in DMEM (GIBCO®, Life Technologies, NY, USA) supplemented with 2mM L-Glutamine, 10% FBS and with 500 units/ml penicillin/streptomycin. All cells were cultured at 37°C and 5% CO₂.

Trypan blue staining analysis

Endometrial cancer cells were plated on a 12-well plate at a density of 1×10^5 cells/well 24 h before cell counting at time 0. We used 0.4% Trypan blue to stain cells and determined cell number using a Countess® Automated Cell Counter (Life Technologies, Carlsbad, CA, USA). Cells were serum-starved for 18 h prior to ligand treatment and then treated with control (DMSO), GW0742, or TTNPB for 24 or 48 h. The concentrations of GW0742 and TTNPB used for all experiments ranged from 0.1 to 10.0 μ M; these were previously shown to specifically activate PPAR / or RAR [18,19]. Cells were counted every 24 h. Triplicate samples for each treatment were used for each time point, and each replicate was counted three times. The average number of cells per well was calculated for each treatment group and recorded as mean $\pm$ standard deviation (SD).

MTS assays

Epithelial endometrial cancer cells (4×10^3 cells/well) were seeded in 96-well plates and grown to 70%–80% confluence in a mixture of DMEM and F12 (1:1) medium containing 10% FBS. After overnight starvation, cells were continually cultured in FBS-free media for 24–48 h in the presence or absence of chemical reagents. Cell proliferation was determined using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. After treatment, 20 μ L of methanethiosulfonate (MTS) assay solution was added to each well and the cells were incubated at 37°C for 4 h. The amount of bio-reduced formazan produced was estimated by measuring the absorbance at 490 nm. All experiments were performed in triplicate.

BrdU-labeling proliferation assay

Cell proliferation in response to different treatments was confirmed using the Cell Proliferation ELISA BrdU (colorimetric) kit (Roche Diagnostics Canada, Quebec, Canada) and analysis was done according to the manufacturer's protocol. Briefly, cells were plated in 96-well plates and treated as described for the cell viability assays. A minimum of 6 replicates were assessed at each dose. BrdU (10 μ M) was added two hours prior to the end of each measurement period. The cells were fixed, lysed, and then treated for 3 minutes with peroxidase-conjugated, anti-BrdU antibody supplied by the manufacturer. The cells were washed three times followed by the addition of substrate solution. Absorbance was measured at 405 nm, with a reference wavelength of 490 nm. Results were recorded as optical density measurements at 405 nm/490 nm. In some wells, cells or BrdU were omitted to serve as negative controls and to estimate the extent of non-specific binding of reagents.

Immunoblot analysis

Endometrial cancer cells were cultured on 60-mm culture dishes. Cells were serum-starved for 18 h and then placed in DMEM without serum with DMSO (control), GW0742, or GW501516. After 24 h of treatment, the cells were washed and isolated using M-PER (Life Technologies, NY, USA) lysis buffer containing protease inhibitors.

A total of 20 µg of protein per sample was resolved using sodium dodecyl sulfate-polyacrylamide gels. Proteins were then electro-transferred onto PVDF membranes (90 V for 90 minutes). The membrane was blocked with 5% non-fat milk powder in TBS-T buffer for 60 minutes. Membranes were then washed and incubated with primary antibodies overnight at 4°C. Membranes were washed with TBS-T, incubated with a secondary peroxidase-conjugated antibody for 60 minutes, and washed. Bands were visualized by enhanced chemiluminescence (ECL) and exposed to X-ray film. Beta-actin was detected to ensure equal protein loading. Independent triplicate samples were analyzed for each treatment group.

The following antibodies were used: PARP, caspase9, cleaved-caspase9, anti-Akt, anti-phospho-Akt, anti- β -catenin, anti-phospho- β -catenin, anti-GSK3 and anti-phospho-GSK3 (all from Cell Signaling Technology, Danvers, MA, USA), and anti- β -actin (Rockland, Gilbertsville, PA, USA). Antibodies against RAR and PPAR γ were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

RNA extraction and quantitative real-time RT-qPCR

Total RNA from cell samples was isolated using TRIzol reagent (Life Technologies, NY, USA) following the manufacturer's protocol. One microgram of RNA was then used to make cDNA using q-script cDNA SuperMix (QuantaBiosciences, Gaithersburg, MD, USA). Real-time quantitative PCR was performed with the ABI 7900 Sequence Detection and the ABI Power Sybr Green gene expression systems (Applied Biosystems, Foster City, CA, USA). Messenger RNA levels for PPAR γ , RAR α , CYP26A1, ANGPTL4, and GAPDH were quantified. GAPDH was used for normalization. Relative quantification of mRNA species was done using the comparative threshold (CT) cycles method. For each sample, we normalized the gene CT value using the formula: $CT = CT_{\text{gene}} - CT_{\text{GAPDH}}$. For relative expression levels, the following formula was used: $CT = CT_{\text{sample}} - CT_{\text{calibrator}}$. This value was then used to plot the gene expression employing the formula 2^{-CT} . Commercially available primers were used for PPAR γ , RAR α , CRABP2, FABP5, CYP26A1, ANGPTL4, and GAPDH (QIAGEN, Valencia, CA, USA).

Transient transfection of siRNA

For in vitro knockdown experiments, three different double-stranded siRNAs against PPAR γ as well as nontargeting siRNA, were designed and synthesized by IDT company (Integrated DNA Technologies, Inc. Iowa, USA). The detailed sequences are shown in Online Resource 1. Cells were seeded in six-well plates at a concentration of 1×10^5 cells/well. When the cells reached 70% confluence, 10 nM of siRNAs were transfected using Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer's recommendations. We incubated the cells for 48–72 h to allow knockdown of PPAR γ . The transfection and silencing efficiency were monitored by qPCR. The endometrial cancer cells were divided into three groups: a non-transfected control group, a negative control group that was transfected with negative control siRNA (siRNA-NC), and the experimental transfected group. Cells were used for further assays.

Phosphokinase proteome profiling

Endometrial cancer cells were plated in 100-mm tissue culture dishes and cultured in DMEM supplemented with 10% FBS until they reached 70% confluence. After serum starvation for 18 h, cells were then cultured in phenol red-free DMEM supplemented with or without 10 μ M GW0742 for 24 hours. Cells were then processed following the human phosphokinase array kit (Proteome Profiler™; R&D Systems, Minneapolis, USA) instructions. Phosphokinase array data were developed on X-ray films following exposure to chemiluminescent reagents.

Statistical analysis

All data were reported as mean $\pm$ SE from at least three independent experiments. Statistical differences between samples were determined by one-way ANOVA followed by *post-hoc* multiple comparison testing using the Neuman–Keuls procedure. $P < 0.05$ was considered statistically significant.

Results

Human endometrial cancer cell lines express PPAR β/δ and RAR α

We investigated the expression of PPAR β/δ and RAR α in the Ishikawa, RL-95, and Sawano human endometrial cancer cell lines using quantitative reverse-transcriptase-PCR (qRT-PCR). As shown in Figure 1a, RAR α mRNA expression varied among the cell lines, with the highest expression of RAR α observed in the Sawano cells. Expression of PPAR β/δ mRNA was similar among the three endometrial cancer cell lines. Similar results were observed at the protein level, as shown in Figure 1b, PPAR β/δ expression was comparable among all three cell lines, and RAR α protein levels were the highest in the Sawano cell line.

Endometrial cancer cell proliferation is suppressed in the presence of PPAR β/δ and RAR α -selective agonists

To determine the function of PPAR β/δ and RAR α in endometrial cancer cells, we treated the cells for 24–48 hours with either GW0742, a high affinity PPAR β/δ -selective agonist, or TTNPB, an RAR α -selective agonist and quantified total cell number following treatment. As shown in (Figure 2a–c), we found that after 48h treatment, the total cell numbers significantly decreased in all three endometrial cancer cell lines treated with 10 μ M TTNPB compared with controls. These results support previous data showing that activation of RAR α inhibits cell proliferation [20]. Interestingly, a similar anti-proliferative effect was observed in the three cell lines treated with GW0742, where total cell number decreased significantly 24h and 48h following 10 μ M GW0742 treatment (Figure 2d–f), indicating that like RAR α , PPAR β/δ may be a promising therapeutic target for endometrial cancer.

To further assess the effect on endometrial cancer cell viability, we used an MTS assay after TTNPB and GW0742 treatment. We observed that 10 μ M TTNPB markedly decreased the viability of all three cell lines in a time- dependent manner (Online Resource 2 a–c). A similar decrease in cell viability was observed with 10 μ M GW0742 treatment (Online Resource 2 d–f). These results demonstrate that, similar to RAR α , ligand activation of PPAR β/δ inhibits the proliferation of human endometrial cancer cell lines. Given that the therapeutic potential of targeting RAR α with selective agonists was previously established in endometrial carcinoma [15], we focused the rest of our studies on characterizing the therapeutic potential of PPAR β/δ in endometrial cancer.

PPAR β/δ -selective agonists decrease growth and increase apoptosis in human endometrial cancer cell lines

We used BrdU labeling to further confirm the growth-inhibiting effect of the PPAR β/δ -selective agonists GW0742 and GW501516 on the three endometrial cancer cell lines (Figure 3). Although slight decreases in proliferation were observed after 24 and 48-hours of PPAR β/δ -selective agonist treatment in the RL-95 and Sawano cell lines, only the 10 μ M dose significantly decreased proliferation at these time points (Figure 3 a–c). Similar results were observed in the Ishikawa cell line, where 10 μ M GW501516 and GW0742 significantly decreased cell proliferation after 24 and 48-hours of treatment (Figure 3a). Regarding apoptosis, we found that GW501516 and GW0742 also increased apoptosis in the three cell lines, as measured by cleaved poly (ADP-ribose) polymerase (PARP) and cleaved caspase-9 levels (Figure 3d). We observed that 10 μ M GW501516 and GW0742 induced the cleavage of PARP and caspase-9 24 hours post-treatment. To verify the ability of the PPAR β/δ -selective agonists to induce apoptosis on an alternate human epithelial cell line, we treated the human keratinocyte cell line (HaCaT), with both GW0742 and GW501516 for 24 hours (Online Resource 3). We observed that similar to the effects observed in the endometrial cancer cells, 10 μ M GW501516 and GW0742 induced PARP cleavage in the HaCaT cells. Given that significant changes were observed within 24 hours and using 10 μ M GW501516 and 10 μ M GW0742 treatment, we concluded that this dose was necessary to exert significant effects on cell proliferation and apoptosis.

To confirm activation of PPAR β/δ by the two tested agonists, we quantified the gene expression levels of a well-characterized PPAR β/δ target gene, angiopoietin-like protein 4 (ANGPTL4) [21] in the three endometrial cancer cell lines after treatment with either GW0742 or GW501516 at all three doses. As expected, we observed that ANGPTL4 gene expression significantly increased in all cell lines in response to the 1 μ M and 10 μ M concentration of both agonists (Online Resource 4 a,b).

PPAR β/δ antagonists abolish the anti-proliferative and apoptotic effects of PPAR β/δ activation

Next, we examined the ability of the PPAR β/δ -selective antagonists GSK3787 and GSK0660 to attenuate the observed apoptotic and anti-proliferative effects of the PPAR β/δ -selective agonists (GW0742 and GW501516) in the three human endometrial cancer cell lines (Figure 4). BrdU labeling was performed after a 4 hour pretreatment with either of the two PPAR β/δ -selective antagonists, followed by a 24-hour treatment with 10 μ M concentrations of either PPAR β/δ -selective agonist. Pretreatment with either PPAR β/δ -selective antagonist completely abolished the anti-proliferative effects elicited by the selective PPAR β/δ agonists in all three endometrial cancer cell lines (Figure 4a–c). Apoptosis markers induced by the PPAR β/δ -agonists were also decreased in Ishikawa, RL-95 and Sawano cells following the same treatment conditions, consisting of a 4 hour antagonist pretreatment followed by 24 hour treatment of 10 μ M GW0742 or 10 μ M GW501516 (Figure 4d–e). These results demonstrate the specificity of PPAR β/δ effects on endometrial cancer cell proliferation and apoptosis.

PPAR β/δ knockdown eliminates the effects of PPAR β/δ -selective agonists on endometrial cancer cell apoptosis and gene expression

We knocked down PPAR β/δ expression with RNAi to confirm the functional importance of PPAR β/δ in mediating apoptosis in the three endometrial cancer cell lines. Successful PPAR β/δ gene silencing with two different siRNA oligos was confirmed by qRT-PCR (Online Resource 5 a–c) and immunoblot (Online Resource 5d). Control and siRNA-transfected cells were treated with the PPAR β/δ -selective agonist GW0742 (10 μ M, 24h), and the protein levels of cleaved PARP were examined by immunoblot to determine

apoptosis (Figure 5a). As observed in our previous experiments, GW0742 induced PARP cleavage, whereas this effect was completely reversed with siRNA knockdown of PPAR γ . This indicates that the GW0742-induced apoptotic effects are mediated via PPAR γ activity.

Others have suggested that the transactivation of RAR α or PPAR γ is dependent not only on the ratio of fatty acid binding protein 5 (FABP5) to cellular retinoic acid binding protein II (CRABP-II) but also on the RAR α and PPAR γ expression levels [13]. This model suggests that in the absence of PPAR γ expression, the PPAR γ -selective agonist could transactivate RAR α and induce target gene expression. Although we obtained significant PPAR γ knockdown, transactivation of the classic RAR α -target gene, *CYP26A1* [15,22], was not observed (Figure 5b–d). These results suggest that the effects of GW0742 were primarily mediated by PPAR γ . However, we did observe a reduction in the classic PPAR γ target gene expression- *ANGPTL4* mRNA levels significantly decreased after PPAR γ knockdown even in the presence of 10 μ M GW0742 for 24 hours (Figure 5b–d). This indicates that siRNA-mediated knockdown of PPAR γ indeed decreases its transcriptional activity.

Activation of PPAR β/δ inhibits the proliferation of endometrial cancer cells through the AKT/GSK3 β / β -catenin pathway

To characterize the mechanism by which PPAR γ activation exerts anti-proliferative and apoptotic effects on endometrial cancer cells, we analyzed the expression of PTEN and AKT phosphorylation following GW0742 treatment. Others have shown that the AKT pathway is affected following the activation of PPAR γ by selective agonists [23]. Following treatment with increasing concentrations of the PPAR γ -selective agonist GW0742, all three cancer cell lines demonstrated increased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) (2.7-fold, 1.7-fold, and 4.3-fold increase after 10 μ M treatment in Ishikawa, RL-95, and Sawano cells respectively, relative to vehicle) and lower phosphorylation of AKT (0.4-fold, 0.4-fold, and 0.6-fold decrease after 10 μ M treatment in Ishikawa, RL-95, and Sawano cells, respectively, relative to vehicle) (Figure 6a). To fully characterize the signaling pathways affected by ligand activation of PPAR γ , we profiled 46 kinases and protein substrates using a phosphokinase array (Figure 6b). All three cell lines were treated with 10 μ M GW0742 for 24 hours and cell lysates were hybridized to membranes to identify signaling pathways that were affected by PPAR γ activation. We found changes in the phosphorylation of GSK3 β , AKT, and β -catenin after GW0742 treatment that were consistent among all three endometrial cancer cell lines (see coordinates A5, B5 and C5 on Figure 6b and highlighted rows in Table 1). PPAR γ activation also resulted in decreased phosphorylation of AKT at Ser473 and decreased GSK3 β phosphorylation, whereas β -catenin phosphorylation was markedly increased upon GW0742 treatment (Figure 6b). The changes observed in the phosphokinase array were further validated in the endometrial cancer cell lines by immunoblot (Figure 6c). The immunoblot results in fact validated the GW0742-induced changes on the phosphorylation states of AKT (0.7-fold, 0.5-fold, and 0.5-fold decrease after 10 μ M GW0742 treatment in Ishikawa, RL-95, and Sawano cells, respectively), GSK3 β (0.6-fold, 0.5-fold, and 0.1-fold decrease in Ishikawa, RL-95, and Sawano cells, respectively) and β -catenin (2.9-fold, 3.7-fold, and 3.9-fold increase in Ishikawa, RL-95, and Sawano cells, respectively), indicating that ligand activation of PPAR γ by GW0742 affects the AKT/GSK3 β / β -catenin signaling pathway.

Effect of ligand activation of PPAR β/δ on the AKT/GSK3 β / β -catenin pathway can be attenuated by PPAR β/δ knockdown and lithium

To assess the specificity of PPAR β/δ -induced changes on the regulation of the AKT/GSK3 β -catenin signaling pathway, we performed siRNA knockdown of the receptor in combination with 10 μ M GW0742 for 24 hours. siRNA knockdown of PPAR β/δ in the three endometrial cancer cell lines reversed the GW0742-induced effects on AKT, GSK3 β -catenin (Figure 7a). Specifically, we observed that compared to the controls, PPAR β/δ knockdown reversed the GW0742-induced decrease in AKT phosphorylation (from 0.5 to 1.1, 0.4 to 1.0, and 0.3 to 1.3-fold increase in Ishikawa, RL-95 and Sawano cells treated with siPPAR β/δ #2, respectively), and abolished the observed increase in phospho- β -catenin (from 3.3 to 1.2, 7.1 to 0.9, and 5.3 to 1.1-fold decrease in Ishikawa, RL-95 and Sawano cells treated with siPPAR β/δ #2, respectively), (Figure 7a). Similarly, the GW0742-induced decrease in GSK3 β phosphorylation was reversed by PPAR β/δ knockdown (from 0.6 to 1.0, 0.8 to 1.4, and 0.4 to 0.9-fold increase in Ishikawa, RL-95, and Sawano cells treated with siPPAR β/δ #2, respectively) in Figure 7a. These results demonstrate the specificity of the receptor in regulating the AKT/GSK3 β -catenin signaling pathway.

We used lithium as a signaling pathway inhibitor to test the specificity of PPAR β/δ on the AKT/GSK3 β -catenin signaling pathway. Lithium is known to induce the phosphorylation and activation of AKT and to have inhibitory effects on GSK3 β [24,25]. We pre-treated the cancer cell lines with lithium prior to GW0742 treatment to test the ability of lithium to reduce the GW0742-mediated effects. In the samples treated with the combination of lithium and GW0742, lithium attenuated the apoptotic effects of PPAR β/δ activation, as indicated by decreased levels of cleaved PARP (Figure 7b). We also observed that compared to the GW0742-treated samples, the combination of lithium and GW0742 restored the phosphorylation of both AKT (from 0.5 to 1.0, 0.6 to 1.2, and 0.8 to 1.2-fold increase in Ishikawa, RL-95 and Sawano cells lines, respectively) and GSK3 β (from 0.3 to 1.4, 0.5 to 0.9, 0.6 to 1.0-fold increase, in Ishikawa, RL-95, and Sawano cells, respectively) (Figure 7b). Similarly, the combination of GW0742 and lithium restored the levels of β -catenin phosphorylation (from 1.8 to 1.2, 1.4 to 0.8, and 1.5 to 1.1-fold change in Ishikawa, RL-95, and Sawano cells, respectively), leading to a modest decrease in β -catenin phosphorylation in all three endometrial cancer cell lines. Overall, these results indicate that the ligand-mediated effects of PPAR β/δ on endometrial cancer cell apoptosis can be abrogated through the lithium-based pharmacologic activation of the AKT/GSK3 β -catenin pathway.

Discussion

In this study, we demonstrated that ligand-activated PPAR β/δ regulates the proliferation and apoptosis of three different human endometrial cancer cell lines, and that the AKT/GSK3 β -catenin pathway is involved in mediating these effects. PPAR β/δ activated with highly selective synthetic ligands led to a decrease in cell proliferation and an increase in markers of apoptosis (cleaved PARP and caspases). PPAR β/δ knockdown as well as pre-treating the cells with PPAR β/δ antagonists or lithium could attenuate these effects. Our work reveals a unique function of PPAR β/δ in endometrial cancer cells and strongly supports the hypothesis that modulating PPAR β/δ activity may be a key therapeutic target for endometrial cancer interventions.

As a nuclear receptor involved in multiple physiological regulatory pathways, PPAR β/δ is an ideal drug target for the treatment of disease. However, the role of PPAR β/δ in human cancer has remained controversial because of disparities in the literature. Previous work by some laboratories suggested that activation of PPAR β/δ increased cell growth, while others showed that this effect was seen in only some cell types. Given the potential of targeting

PPAR γ for the prevention and/or treatment of cancer, it is important to clarify the functional role of PPAR γ in cell proliferation and survival.

PPAR γ can be activated by several commercially available high-affinity synthetic PPAR γ ligands, including GW0742, GW501516, and L165041. These ligands can activate PPAR γ at concentrations in the low nM to μ M range [17,26]. In this study, we exposed three different endometrial cancer cell lines to the ligands GW0742 and GW501516. Our results provide convincing evidence that in endometrial cancer cells, PPAR γ agonists decrease endometrial cancer cell proliferation and survival. We find that while PPAR γ agonists exert dose-dependent effects on target gene expression, the high 10 μ M dose was necessary to significantly affect the AKT/GSK3 β -catenin pathway and induce changes in proliferation and apoptosis. It is plausible that lower concentrations of these agonists can induce expression of individual genes, whereas high doses are necessary to alter more complex cellular events such as apoptosis or signal pathway activation, which may require coordinated changes in expression of a large number of genes. Overall, the observation of PPAR γ regulating cell proliferation and survival is consistent with previous work showing the PPAR γ -dependent inhibition of cell proliferation in keratinocytes and various human cancers [7,27–30].

Because of the conflicting evidence, no unified, universally accepted mechanism of action has been put forward to describe the role of PPAR γ in cancer. Several mechanisms have been proposed to explain the observed pro-carcinogenic effects of PPAR γ , partly based on data from normal mouse primary keratinocytes [31]. Analyses of these cells suggested that the high ratio of intracellular FABP5 to CRABP II diverts *all*-RA or PPAR γ ligands to PPAR γ rather than to the RAR α . This is thought to increase PDK1 to protect against apoptosis and increase cell survival. However, follow-up studies, including ours, have not validated this model [13,14].

Another mechanism suggests that PPAR γ promotes cell survival via regulation of the ILK-PDK1-PTEN-AKT pathway. The tumor suppressor gene PTEN, a negative regulator of the PI3K/AKT signaling pathway, can modulate cell growth, proliferation, and survival. PPAR γ was originally shown to inhibit the expression of PTEN in keratinocytes during wound healing [23]. Other studies found that this change in PTEN is not consistent [29,32–34], and that the up-regulation of PTEN expression by activated PPAR γ is context specific. Our study showed increased PTEN expression in the endometrial cancer cells treated with the PPAR γ agonist GW0742. Although we did not directly determine the effects of activated PPAR γ on PI3K activity, we did detect a loss of phosphorylated AKT, a known downstream target of PI3K. These results suggest that activated PPAR γ increases PTEN expression and down-regulates the AKT signaling pathway to suppress proliferation and stimulate apoptosis in endometrial cancer cells.

Glycogen synthase kinase 3 (GSK3) proteins are serine/threonine kinases that were originally identified as key regulatory enzymes in glucose metabolism [35]. There are two isoforms, GSK3 α and GSK3 β that are encoded by separate genes [36]. GSK3 β is an important effector of AKT activity and is also an important element of the PI3K/AKT cell survival pathway [37]. The activity of GSK3 β is regulated by phosphorylation on the Ser9 residue, and abnormal regulation of GSK3 β is associated with various pathological conditions. Many upstream protein kinases, including AKT/PKB [38], are known to phosphorylate GSK3 β at Ser9, depending on the cellular context and on various upstream regulators. In recent years, the role of GSK3 β in cancer has become firmly established [39]. For example, it is known that GSK3 β plays a major role in epithelial cell homeostasis and is a key factor in human cancers, regulating transcription, contributing to accelerated cell cycle progression and to cancer cell metastasis and anti-apoptosis [40]. Despite its well-

established role in other cancers, a detailed analysis of GSK3 in endometrial cancer and its therapeutic potential is still lacking.

In our study, GW0742 inactivated AKT and effectively decreased the phosphorylation of AKT on Ser473 in the endometrial cancer cell lines we tested. AKT phosphorylation negatively regulates GSK3 activity by phosphorylating it on Ser9 [41]. In our study, we observed that ligand activation of PPAR γ decreased the phosphorylation levels of AKT and GSK3. GSK3 is known to phosphorylate β -catenin, an integral component of the canonical Wnt signaling pathway [42]. Unphosphorylated β -catenin is stable and accumulates in the cytoplasm; its nuclear translocation allows it to act as a transcriptional cofactor to promote cell survival and proliferation [43]. In our study, ligand activation of PPAR γ in endometrial cancer cell lines led to the increased phosphorylation of β -catenin, which has been previously shown to target it for proteosomal degradation [42]. Furthermore, lithium, which is known to indirectly regulate GSK3 through the PI3K/AKT pathway [24,44], can enhance GSK3 activation and rescue the endometrial cancer cell lines from PPAR γ -induced apoptosis. Together, these results may partly explain the mechanism by which the PPAR γ -selective agonists cause apoptosis in endometrial cancer cells. These data also suggest that GSK3 may be a promising therapeutic target in endometrial cancer, and pursuit of this therapeutic strategy is warranted.

Based on the findings described above, we propose a model (Figure 8) for the role of PPAR γ in modulating cell proliferation and apoptosis in endometrial cancer cells. After activation of PPAR γ , increased PTEN generation leads to decreased phosphorylation of AKT and GSK3. These changes increase the phosphorylation of β -catenin, a post-translational modification that targets it for ubiquitin-dependent proteosomal degradation. Taken together, our findings indicate that in endometrial cancer cells, PPAR γ activation prevents cell proliferation and causes apoptosis, and that the regulation of the AKT/GSK3 / β -catenin pathway is involved.

In conclusion, we demonstrated that ligand-activated PPAR γ regulates cell proliferation and apoptosis in endometrial cancer cells and that upregulation of PTEN and modulation of the AKT/GSK3 / β -catenin pathway may be involved. A full characterization of this pathway will be addressed in future studies. These results have important implications not only for understanding the molecular mechanisms of PPAR γ in endometrial cancer, but also by providing novel insights into the treatment of endometrial cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Wright JD, Barrena Medel NI, Sehoul J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. *Lancet*. 2012; 379:1352–1360. [PubMed: 22444602]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin*. 2013; 63:11–30. [PubMed: 23335087]
3. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet*. 2010; 375:816–823. [PubMed: 20206777]
4. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. *Clin Cancer Res*. 2012; 18:5856–5864. [PubMed: 23082003]
5. Panigrahy D, Kaipainen A, Kieran MW, Huang S. PPARs: A Double-Edged Sword in Cancer Therapy? *PPAR Res*. 2008; 2008:350351. [PubMed: 19590598]

6. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. *Endocrinology*. 2003; 144:2201–2207. [PubMed: 12746275]
7. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. *Cell Signal*. 2006; 18:9–20. [PubMed: 16109478]
8. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. *Nat Rev Cancer*. 2012; 12:181–195. [PubMed: 22318237]
9. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. *Cell*. 1995; 83:841–850. [PubMed: 8521508]
10. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. *Neoplasia*. 2000; 2:483–490. [PubMed: 11228540]
11. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. *Nat Rev Cancer*. 2004; 4:61–70. [PubMed: 14708026]
12. Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. *Br J Pharmacol*. 2011; 164:68–82. [PubMed: 21449912]
13. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. *Cell*. 2007; 129:723–733. [PubMed: 17512406]
14. Rieck M, Meissner W, Ries S, Muller-Brusselbach S, Muller R. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. *Mol Pharmacol*. 2008; 74:1269–1277. [PubMed: 18701617]
15. Cheng YH, Utsunomiya H, Pavone ME, Yin P, Bulun SE. Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms. *J Mol Endocrinol*. 2011; 46:139–153. [PubMed: 21310893]
16. Pelton P. GW-501516 GlaxoSmithKline/Ligand. *Curr Opin Investig Drugs*. 2006; 7:360–370.
17. Sznajdman ML, Haffner CD, Maloney PR, Fivush A, Chao E, et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. *Bioorg Med Chem Lett*. 2003; 13:1517–1521. [PubMed: 12699745]
18. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, et al. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. *Mol Pharmacol*. 2010; 78:419–430. [PubMed: 20516370]
19. Bissonnette RP, Brunner T, Lazarchik SB, Yoo NJ, Boehm MF, et al. 9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. *Mol Cell Biol*. 1995; 15:5576–5585. [PubMed: 7565709]
20. Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS, et al. Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. *Oncogene*. 1998; 16:3471–3480. [PubMed: 9692555]
21. Heinaniemi M, Uski JO, Degenhardt T, Carlberg C. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. *Genome Biol*. 2007; 8:R147. [PubMed: 17650321]
22. Mahony S, Mazzoni EO, McCuine S, Young RA, Wichterle H, et al. Ligand-dependent dynamics of retinoic acid receptor binding during early neurogenesis. *Genome Biol*. 2011; 12:R2. [PubMed: 21232103]
23. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. *Mol Cell*. 2002; 10:721–733. [PubMed: 12419217]
24. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. *Proc Natl Acad Sci U S A*. 1999; 96:8745–8750. [PubMed: 10411946]
25. Noble W, Planel E, Zehr C, Olm V, Meyerson J, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proc Natl Acad Sci U S A*. 2005; 102:6990–6995. [PubMed: 15867159]

26. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. *J Biol Chem.* 1999; 274:6718–6725. [PubMed: 10037770]
27. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. *J Cell Biol.* 2001; 154:799–814. [PubMed: 11514592]
28. Peters JM, Lee SS, Li W, Ward JM, Gavrilo O, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). *Mol Cell Biol.* 2000; 20:5119–5128. [PubMed: 10866668]
29. Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, et al. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. *Carcinogenesis.* 2007; 28:2641–2649. [PubMed: 17693664]
30. Fukumoto K, Yano Y, Virgona N, Hagiwara H, Sato H, et al. Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. *FEBS Lett.* 2005; 579:3829–3836. [PubMed: 15978581]
31. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. *Biochim Biophys Acta.* 2009; 1796:230–241. [PubMed: 19505534]
32. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, et al. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. *Cell Death Differ.* 2006; 13:53–60. [PubMed: 16021179]
33. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, et al. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. *Cancer Res.* 2006; 66:4394–4401. [PubMed: 16618765]
34. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, et al. Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. *Cell Signal.* 2007; 19:1163–1171. [PubMed: 17254750]
35. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. *Biochem J.* 2001; 359:1–16. [PubMed: 11563964]
36. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. *EMBO J.* 1990; 9:2431–2438. [PubMed: 2164470]
37. Fung TK, Gandillet A, So CW. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/beta-catenin pathway. *Curr Opin Hematol.* 2012; 19:280–286. [PubMed: 22525581]
38. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature.* 1995; 378:785–789. [PubMed: 8524413]
39. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. *Mol Cancer.* 2010; 9:144. [PubMed: 20537194]
40. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. *Cancer Lett.* 2009; 273:194–200. [PubMed: 18606491]
41. Muyliaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, et al. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? *Genes Brain Behav.* 2008; 7(Suppl 1): 57–66. [PubMed: 18184370]
42. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. *Prog Neurobiol.* 2001; 65:391–426. [PubMed: 11527574]
43. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. *Dev Cell.* 2009; 17:9–26. [PubMed: 19619488]
44. Rowe MK, Chuang DM. Lithium neuroprotection: molecular mechanisms and clinical implications. *Expert Rev Mol Med.* 2004; 6:1–18. [PubMed: 15488156]

Fig. 1. PPAR β/δ and RAR α expression in Ishikawa, RL-95 and Sawano endometrial cancer cells (a) PPAR β/δ and RAR α mRNA expression by RT-qPCR. (b) Immunoblot of endometrial cancer cell lines to detect protein expression of PPAR β/δ and RAR α .

Fig. 2. PPAR γ and RAR α -selective agonists suppress proliferation of three different endometrial cancer cell lines (**a-f**) Cells were treated for up to 48 hours with the indicated ligand concentrations and cell number was obtained using Trypan blue exclusion. (**a**) Ishikawa cells, (**b**) RL-95 cells, and (**c**) Sawano cells treated with increasing concentrations of TTNPB; (**d**) Ishikawa cells, (**e**) RL-95 cells, and (**f**) Sawano cells treated with increasing concentrations of GW0742. Values represent the mean $\pm$ standard error of the mean for experiments run in triplicate. # Significantly different than DMSO control, $P < 0.05$.

Fig. 3.

PPAR / -selective agonists GW0742 and GW501516 inhibit growth and activate apoptosis of endometrial cancer cells. Cells were treated for up to 48 hours with the indicated ligand concentrations and cell proliferation was examined using BrdU incorporation assay in (a) Ishikawa, (b) RL-95, and (c) Sawano cells. (d) Immunoblot of apoptosis markers after treatment of cells with 0.1–10 μM GW0742 or GW501516 for 24 hours. Cleaved PARP and cleaved caspase-9 were present in all three cell lines. Hybridization signals were normalized to β -actin. Values represent the mean $\pm$ standard error of the mean for experiments run in triplicate. #Significantly different from control, $P < 0.05$. (U) indicates uncleaved PARP and (C) indicates cleaved PARP. Blots are representative of $n=3$ replicates.

Fig. 4.

Pretreatment with selective PPAR / antagonists completely abolishes the anti-proliferative and apoptotic effects of PPAR / treatment. Cell proliferation measured by BrdU assay after a 4 hour pretreatment of (a) Ishikawa, (b) RL-95, and (c) Sawano cell lines with either GSK3787 or GSK0660 PPAR / antagonist followed by treatment with 10 μ M of either GW0742 or GW501516 PPAR / agonist for 24 hours. Values represent the mean $\pm$ standard error of the mean for experiments run in triplicate. #Significantly different from control, $P < 0.05$. (d-e) Immunoblot of apoptosis markers in cells pretreated for 4 hours with either GSK3787 or GSK0660 PPAR / selective antagonist followed by treatment with 10 μ M concentration of (d) GW0742 or (e) GW501516 for 24 hours. (U) indicates uncleaved PARP and (C) indicates cleaved PARP. Blots are representative of n=3 replicates.

Fig. 5. PPAR / knockdown attenuates the agonist-mediated apoptotic effects and target gene expression in endometrial cancer cells. **(a)** The effect of PPAR / knockdown on PPAR / -activated PARP cleavage was evaluated by immunoblot in the three endometrial cancer cell lines. Cells were treated with GW0742 (10 μ M) for 24 hours before assessing the effects on apoptosis. **(b-d)** The effect of PPAR / knockdown on expression of the PPAR / -dependent target gene ANGPTL4 and the RAR -target gene CYP26A1 was determined by qRT-PCR in **(b)** Ishikawa, **(c)** RL-95, and **(d)** Sawano cells following ligand activation of PPAR / with 10 μ M GW0742 for 24 h. Fold induction of mRNA was calculated from data normalized to GAPDH mRNA relative to control for each cell line. Values represent the mean $\pm$ standard error of the mean for experiments run in triplicate. #Significantly different from control, $P < 0.05$. (U)indicates uncleaved PARP and (C) indicates cleaved PARP. Blots are representative of $n=3$ replicates.

Fig. 6. PPAR / activation regulates components and protein targets of the AKT signaling pathway (a) Immunoblots showing increased PTEN and decreased phosphorylation of AKT in all three cell lines following 24 hours of increasing GW0742 concentrations. (b) Representative images from the phosphokinase arrays of Ishikawa, RL-95, and Sawano cells treated with GW0742 (10 μM) for 24 hours. The red boxes outline the proteins that changed consistently after GW0742 treatment in all three cell lines. The red boxes correspond to the following coordinates, A5 (GSK3), B5 (pAKT) and C5 (-catenin). Each kinase is spotted in duplicate and the pairs of dots in each corner are positive controls. (c) Immunoblots demonstrating the effect of GW0742 treatment (10 μM, 24h) on the phosphorylation of AKT and the downstream effectors GSK3 , -catenin, and other protein targets of the AKT pathway. -actin served as the loading control. Hybridization signals were normalized to -actin and are presented as the fold change as compared to the control. Blots are representative of n=3 replicates.

Fig. 7. PPAR γ knockdown or lithium treatment attenuate the PPAR γ -effects on the AKT/ GSK3 β -catenin pathway and apoptosis **(a)** Immunoblot of phosphorylated AKT, GSK β , and β -catenin in control cells or cells transfected with PPAR γ siRNA or a non-targeting siRNA (N-con) and treated with GW0742 (10 μ M, 24h). **(b)** Immunoblot of PARP and phosphorylated AKT, GSK3 β , and β -catenin after pretreatment of cancer cells with lithium and subsequent 24 hour GW0742 (10 μ M, 24h) treatment. (U) indicates uncleaved PARP and (C) indicates cleaved PARP. Hybridization signals were normalized to β -actin and are presented as the fold change as compared to the control. Blots are representative of n=3 replicates.

Fig. 8.

Diagram demonstrating the ligand activated-PPAR / regulation of proliferation and apoptosis of endometrial cancer cells. Ligand activation of PPAR / increases PTEN expression and leads to decreased AKT phosphorylation on S473. Consequently, this reduction in Akt phosphorylation results in the reduced phosphorylation of GSK-3 that, in turn, decreases the stability of the -catenin complex. Finally, destabilization and degradation of -catenin is observed as its phosphorylation increases, resulting in decreased proliferation and apoptotic activation of the endometrial cancer cells.

Table 1

Phospho-kinase array coordinates used to identify PPAR / -regulated signaling pathways in endometrial cancer cells.

Membrane/Coordinate	Target	Cell type		
		Ishikawa	RL-95	Sawano
A1	Reference			
A2	p38			
A3	ERK1/2			
A4	JNK pan			
A5	GSK-3 / , S21/S9			
A7	p53			
A9	Reference			
B2	MEK1/2			
B3	MSK1/2			
B4	AMPK 1			
B5	Akt, S473			
B7	p53(s15)			
C1	TOR			
C2	CREB			
C3	HSP27			
C5	-Catenin			
C6	p70 S6 Kinase			
C8	P27			
D1	Src			
D2	Lyn			
E1	Fyn			
E2	Yes			
F1	Hck			
F2	Chk-2			
F3	FAK			
F4	STAT6			
F9	negative control			
G1	Reference spot			
G3	negative control			